Nigeria had in some good ways contributed to the global efforts on
New HIV prevention technology research.

1. Phase I CS3 study: Between the 16th of December 2001 and 4th July
2003, the Centre for Research and Reproductive Realth (CRRH),
Sagamu, Nigeria conducted a phase I (safety and acceptability) study on 6% cellulose sulphate trial as a possible microbicide product. This was part of a multicentre study involving 66 women aged 19 to44. the study noted that the product appear to be safe and well tolerated

2. Acceptability study of Nonoxynol 9: In the late `90s Nigeria,
through the University of Port Harcourt, was engaged in an
acceptability study of nonoxynol 9. The study evaluated the
acceptability of Nonoxynol 9 (N9) foam and film. The study was
aborted abruptly following the results of the UNAIDS multi-centre
effectiveness study that showed that N9 increased the risk of HIV
infection. The wealth of information from that data was not shared

3. Lime juice use as microbicide: A feasibility study on the
possible use of lime as a microbicide was conducted in Nigeria in
October 2003. an expanded study was planned following the outcome of
the Nigerian study. However, strong global evidence pointed to the
potential for lime juice to increase risk of HIV infection and thus
plans for the expanded study was aborted.

4. Phase III SAVVY trial: Nigeria was also engaged in the phase III
SAVVY trial – the testing of a potential microbicide to see if it
was effective. The study was conducted in University College
Hospital, Ibadan and the National Institute of Medical Research,
Lagos between 2004 and 2007. 2140 HIV negative women were enrolled into the study. The research was not able to demonstrate that the product was effective in preventing HIV infection

5. Phase III CS3 trial: Phase III CS3 trials were also conducted in
the Lagos University Teaching Hospital, Lagos and the University of
Port Harcourt between 2004 and 2007. 2160 women were to be enorolled into the study. The study was terminated when the conterpart study conducted in South Africa showed that the product had a potential to increase HIV infection in those that used them

6. Phase IIb oral prophylactic use of tenofovir: Nigeria was also
engaged with the study of the possible use of an antiretroviral
(tenofovir) as a possible drug to prevent HIV infection. Past
studies have shown that this concept – the use of a treatment drug
to prevent infection – is feasible as demonstrated with malaria,
tuberculosis and even with the prevention of mother to child
transmission of HIV. The study in Nigeria was however, halted very
early as the study site could not maintain good clinical practice
standards that was satisfactory.

7. TMC 120 microbicide study: A study was conducted in Nassarawa to measure cross- sectional seroincidence (this means doing a research on a number of HIV-infected people you gather together through some recruitment strategies at a single point in time to estimate how many of these people are newly HIV infected every year). This study conducted with IPM has come to an end. The data has been analysed by the investigator and there may be some interesting information to share with the Nigerian populace that we can learn from. Such information may be pointers to the rate of new HIV infection in some populations in Nassarawa State. IPM would however not go into the next phase of research with the site in Nassarawa State. For IPM, the next stage would be to do a prospective sero-incidence study (this is a study in which people who are not infected are followed up for about a year and you determine how many get HIV infection within that period). IPM has decided to concentrate its work in Southern and Eastern African countries for now. Although IPM is not supporting further incidence studies, there is such a study going on currently in Nigeria through HVTN support for future HIV vaccine studies in Nigeria. IPM may consider doing other forms of study in the country, including possible acceptability studies. Currently, potential difficulties in delivering study products in Nigeria through the custom agency is a considerable barrier that the country needs to address to facilitate study efforts.

8. HIV Vaccine studies: There are also indications that there may be
some new HIV Vaccine related studies that would be conducted in the
near future in Nigeria. The Military Hospital is gearing up for
this. There was a sero-incidence study conducted in Asokoro
Hospital, Abuja for this same reason Nigeria has contributed in so many significant ways to the development of New HIV Prevention Technology. We look forward to the country hosting more studies in the future as this may help answer a few peculiar West African related differences in the global epidemiology of HIV infection.